Top 5 pediatric health headlines you missed in August 2026

In this monthly recap, Contemporary Pediatrics reviews the most significant developments shaping pediatric practice and public health. Click each title below for full coverage.

1. Trump signs executive order overhauling childhood vaccine recommendations

President Donald Trump signed an executive order on August 10, 2026, directing federal health officials to overhaul the US childhood vaccine schedule by reducing the number of vaccines routinely recommended for all children and spacing immunizations across separate visits. The order calls for routine recommendations covering 11 rather than 18 diseases, with 7 vaccines shifted to shared clinical decision-making, and encourages separate administration of vaccines, including replacing the combined MMR vaccine with individual measles, mumps, and rubella shots. However, standalone versions are not currently available in the United States. The administration said the changes would more closely align US recommendations with those of other developed countries. At the same time, public health experts warned that spreading vaccinations across additional visits could leave children susceptible to vaccine-preventable diseases for longer periods. The order comes amid declining childhood vaccination rates and elevated measles activity, and its impact on school vaccination requirements will depend largely on individual states. Tina Q. Tan, MD, FAAP, FIDSA, FPIDS, editor-in-chief of Contemporary Pediatrics, warned that the changes could reduce protection against serious vaccine-preventable diseases.

2. Anaphylm sublingual epinephrine film shows improved usability, comparable PK ahead of planned FDA resubmission

Aquestive Therapeutics reported topline human factors and pharmacokinetic results for Anaphylm (dibutepinephrine) sublingual film that the company says address deficiencies identified in the FDA’s January 2026 Complete Response Letter and support a planned NDA resubmission in the third quarter of 2026. In the revised human factors study, median pouch-opening time decreased from 17 seconds to 3 seconds, while difficulties opening the package and errors in film placement declined substantially, with no participants chewing or removing the film. A separate pharmacokinetic study found that self-administered Anaphylm produced epinephrine exposure similar to clinician-administered dosing and reached peak concentration in a median of 12 minutes, compared with 45 minutes for manual intramuscular epinephrine injection. Although the findings suggest that revised packaging and instructions may address the FDA’s concerns, the results are sponsor-reported and have not been peer reviewed or independently evaluated by the agency. If approved, Anaphylm could become the first noninvasive, orally delivered epinephrine product for patients at risk of anaphylaxis.

3. Back-to-school visits offer opportunity to revisit vaccine conversations with families

Back-to-school visits offer pediatricians an opportunity to revisit vaccine discussions with families by focusing on a child’s changing circumstances rather than repeating previous conversations, according to Lori Handy, MD, MSCE, of Children’s Hospital of Philadelphia. Handy recommends connecting vaccination with the increased exposure children may encounter when entering or returning to school, while giving families a clear recommendation and discussing the diseases vaccines prevent rather than relying on vaccine abbreviations. She also emphasized listening to parents’ primary concerns and recognizing that many families arrive with health information obtained online. Rather than dismissing information from social media, pediatricians can acknowledge parents’ questions, share evidence-based information, and direct families toward trustworthy sources on the platforms and in the formats they prefer. This approach can help clinicians maintain trust while ensuring families have reliable information to make vaccination decisions.

4. Permanent Daylight Saving Time could disrupt sleep and school performance in children, expert says

Proposed legislation establishing permanent Daylight Saving Time could affect children’s sleep, academic performance, and safety by creating darker winter mornings and extending evening light exposure, according to pediatric psychologist Dawn Dore-Stites, PhD. The Sunshine Protection Act, which passed the US House of Representatives in July 2026 and awaits Senate action, would eliminate the annual return to Standard Time. Dore-Stites said adolescents may be particularly vulnerable because their naturally later sleep-wake cycles could be further delayed by less morning light, potentially contributing to difficulty waking, daytime sleepiness, and poorer performance in morning classes. Permanent DST could also create safety concerns for younger children waiting for school buses and adolescent drivers traveling in darkness. Pediatricians can help families mitigate sleep disruptions by encouraging consistent bedtimes and wake times, limiting evening light exposure, and maximizing morning and daytime light. Although the American Academy of Sleep Medicine supports eliminating seasonal clock changes, it recommends permanent Standard Time because it more closely aligns with human circadian biology.

5. AAP updates 2026-2027 pediatric influenza vaccine and antiviral recommendations

The American Academy of Pediatrics (AAP) continues to recommend annual influenza vaccination for all children aged 6 months and older without medical contraindications and has updated its guidance for the 2026–2027 season. All available US influenza vaccines are trivalent, and the AAP recommends using any licensed, age- and health-appropriate product without delaying vaccination to obtain a specific formulation. The updated guidance includes expanded recommendations for immunocompromised children and notes that the overall risk of febrile seizures following vaccination remains low. For children with suspected or confirmed influenza, antiviral treatment should begin as early as possible for those who are hospitalized, have severe or progressive illness, are younger than 5 years, or are at increased risk for complications, regardless of vaccination status or symptom duration. Oseltamivir remains the preferred antiviral for both treatment and postexposure chemoprophylaxis when indicated.